Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

Nilar Lwin; Michael Boyle; Joshua S. Davis

doi:10.1093/ofid/ofy027

Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

Nilar Lwin, Michael Boyle, Joshua S. Davis

Research output: Contribution to journal › Article › peer-review

Abstract

Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

Original language	English
Article number	ofy027
Pages (from-to)	1-3
Number of pages	3
Journal	Open Forum Infectious Diseases
Volume	5
Issue number	2
DOIs	https://doi.org/10.1093/ofid/ofy027
Publication status	Published - 1 Feb 2018

Access to Document

10.1093/ofid/ofy027Licence: CC BY-NC-ND

Cite this

@article{1d7331863f85472f8f8f6732fcfaed65,

title = "Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection",

abstract = "Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.",

keywords = "Adalimumab, HIV, Immune reconstitution, Steroid, Tuberculosis",

author = "Nilar Lwin and Michael Boyle and Davis, {Joshua S.}",

year = "2018",

month = feb,

day = "1",

doi = "10.1093/ofid/ofy027",

language = "English",

volume = "5",

pages = "1--3",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

AU - Lwin, Nilar

AU - Boyle, Michael

AU - Davis, Joshua S.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

AB - Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

KW - Adalimumab

KW - HIV

KW - Immune reconstitution

KW - Steroid

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85044416487&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofy027

DO - 10.1093/ofid/ofy027

M3 - Article

C2 - 29507866

AN - SCOPUS:85044416487

VL - 5

SP - 1

EP - 3

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 2

M1 - ofy027

ER -

Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

Abstract

Access to Document

Other files and links

Fingerprint

Cite this